Unilex Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-01-2025
- Paid Up Capital ₹ 0.10 M
as on 03-01-2025
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.26 Cr
as on 03-01-2025
- Revenue 56.94%
(FY 2022)
- Profit 52.61%
(FY 2022)
- Ebitda 44.30%
(FY 2022)
- Net Worth 33.29%
(FY 2022)
- Total Assets 28.82%
(FY 2022)
About Unilex Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.26 Cr.
Hashim Kaithakalathil, Rajesh Rajan, Vimalkumar Viswanathan, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24233KL2011PTC029307
- Company No.
029307
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Unilex Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Rajan  | Managing Director | 10-Aug-2012 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hashim Kaithakalathil | Director | 06-Sep-2011 | Current |
| Vimalkumar Viswanathan | Director | 14-Jun-2013 | Current |
| Narendrakurup Gopakumar | Director | 25-Jul-2016 | Current |
| Rajesh Krishnan | Director | 22-Dec-2016 | Current |
| Suraj Premraj | Director | 28-Aug-2019 | Current |
Financial Performance of Unilex Lifesciences.
Unilex Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 56.94% increase. The company also saw a substantial improvement in profitability, with a 52.61% increase in profit. The company's net worth Soared by an impressive increase of 33.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unilex Lifesciences?
In 2022, Unilex Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Jul 2024 | ₹0.82 M | Open |
Hdfc Bank Limited Creation Date: 11 Dec 2023 | ₹1.31 M | Open |
Hdfc Bank Limited Creation Date: 11 Dec 2023 | ₹0.83 M | Open |
How Many Employees Work at Unilex Lifesciences?
Unilex Lifesciences has a workforce of 41 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unilex Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unilex Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
